Skip to main content

Table 1 Projected Clinical Events per Patient and over Patient Lifetime in the United Kingdom

From: Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation

Events over patient lifetime per patient Aspirin Dabigatran 150 mg Rivaroxaban 20 mg
Total ischaemic stroke events 0.08788 0.06151 0.06151
Δ DOAC vs. Aspirin (Negative = Reduction; Positive = Increase) − 0.02636 − 0.02636
% DOAC vs. Aspirin (Negative = Reduction; Positive = Increase) − 30% − 30%
Total bleeding events 0.91371 1.09226 1.21246
Δ DOAC vs. Aspirin 0.17855 0.29875
% DOAC vs. Aspirin 20% 33%
Haemorrhagic stroke 0.02292 0.01432 0.02360
Δ DOAC vs. Aspirin − 0.00859 0.00069
% DOAC vs. Aspirin − 38% 3%
Other ICH 0.01549 0.01007 0.01596
Δ DOAC vs. Aspirin − 0.00542 0.00046
% DOAC vs. Aspirin − 35% 3%
ECH and CRNM bleeds 0.87530 1.06787 1.17290
Δ DOAC vs. Aspirin 0.19257 0.29760
% DOAC vs. Aspirin 22% 34%
Total events 1.00159 1.15377 1.27397
Δ DOAC vs. Aspirin 0.15218 0.27238
% DOAC vs. Aspirin 15% 27%
  1. Table 1 summarises the projected stroke and bleed events for the United Kingdom. Additional file 1: S5–S8 show the detailed event projections for the other four examined settings. Calculation differs by setting due to minor differences in underlying patient survival